bioRxiv · 10.64898/2026.11.04.764270
RNA-targeted aminopyridine compounds provide a new antifungal strategy
Abstract
While RNA is an emerging therapeutic target class, progress is limited by a shortage of well-defined targets in which ligand binding is coupled to measurable function. The group I intron, a self-splicing ribozyme essential in fungal mitochondria but absent from humans, offers both a tractable platform for exploring first principles of small molecule-RNA targeting and a selective antifungal target. We recalibrated an intron-splicing assay to approximate cellular conditions and performed an extensive, cryo-EM-guided structure-activity relationship campaign against the Candida albicans mtLSU intron. Ligands containing a flexible diamine outperformed conformationally constrained analogues, suggesting a general principle for engaging dynamic RNA surfaces and yielding lead aminopyridine 56 (IC 21.6 nM). Compound 56 synergizes with amphotericin B against C. albicans, suggesting a path for combination therapies. RT-qPCR confirmed direct target engagement in cells. This work establishes the fungal group I intron as a viable, mechanistically distinct antifungal target and a model platform for RNA-targeted discovery.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hwang, J., Sisto, L. J., Shi, T., Van Zandt, M. C., Pyle, A. M.. 2026-11-06. RNA-targeted aminopyridine compounds provide a new antifungal strategy. https://doi.org/10.64898/2026.11.04.764270
Cite the original work for its findings. Save a collection to share your selection of sources.